Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

Recursive self improvement is the key to solving intelligence. Human intelligence is built on our ability to characterize the ...

Recursion Pharmaceuticals is a TechBio company trying to apply artificial intelligence (AI) to the new drug-discovery process. The first placebo-controlled trial results from Recursion Pharmaceuticals ...

Eric Schmidt and other AI leaders (Karpathy, Musk, Anthropic executives) have described recursive self-improvement (RSI)—AI ...

Recursion Pharmaceuticals (RXRX), a trailblazer in AI-powered drug discovery, recently acquired its competitor, Exscientia, in a strategic move that solidifies its leading position in the industry.

Chris Gibson, Recursion Pharmaceuticals CEO, joins 'Closing Bell Overtime' to talk its partnership with Nvidia, its investors day, drug discovery and more. Got a confidential news tip? We want to hear ...